09 April 2021
Visiongain has published a new report on Cell-Based Assays Market Report to 2030: Forecasts by Product (Instruments (Microplates, Microplate Reader, Liquid Handling System), Consumables (Reagents, Assay Kits, Cell Lines, Probes & Labels), Software, Services), by Application (Drug Discovery, Basic Research, ADME Studies, Predictive Technology), by Technology (Automated Liquid Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening), by End-User (Pharma & Biotech Companies, Academic Institutes, CROs) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cell-Based Assays Companies AND COVID-19 Recovery Scenarios.
Global cell-based assay market was valued at US$ xx million in 2020 and is projected to reach at a market value of US$ xx million by 2030. Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
COVID-19 Impact on Cell based assay Market
According to ClinicalTrials.gov, currently, over 2,500 COVID-19 interventional clinical trials have been initiated, with around 600 of these in Phase III. A number of these COVID-19 drug targets have been investigated by researchers in cell‑based assay systems to discover small molecule modulators that can be used to treat the disease. The outbreak of novel COVID-19 is anticipated to create lucrative opportunities in the cell-based assays market due to rising R&D investment for COVID-19 vaccine development and another advanced drug development. During 2021, it is expected that a number of COVID-19 small molecule clinical trials will be completed, with the expectation that a small number of drugs will gain approval for clinical use.
Several manufacturers of vaccines around the world have expanded their testing ability to find an effective coronavirus vaccine. Higher vaccine demand is expected to place pressure on manufacturers and healthcare professionals to supply the vaccine. The increasing number of funding to encourage immunisation and product development by government and private organisations are the key drivers of the demand for cell-based assay.
Cell-based assays, because of their peculiar advantages of predictability, possibility of automation, multiplexing, and miniaturization, seem the most appealing tool for the high demands of the early stages of the drug-discovery process.
Cell-based assays have been a key component in streamlining the drug development process, helping drugs be brought to the market in a quick and efficient manner, and their technological evolution is not slowing down. While cytotoxicity remains a primary effect that drug developers use cell-based assays to quantify, biological activity, biochemical mechanisms and off-target interactions are also being investigated using this technique. Due to their amenability to miniaturization and multiplexing, cell cultures are being used for high-throughput screening (HTS) to test many compounds under different conditions in parallel. Today, cell-based assays are used in more than half of all high-throughput drug screenings for target validation and ADMET (absorption, distribution, metabolism, elimination and toxicity) in the early stage of drug discovery. Additionally, cell-based assays are the preferred tool for screening potential drug compounds and toxicity screening, driving the demand by drug development companies. The demand for cell-based assays will expand further due to increased allocation of resources towards drug discovery by companies, the presence of a large number of proteins which still have unknown functions, and the rising demand for biological drugs.
Cell based assays is gaining increasing acceptance in assessing potency of drugs. Potency of biotherapeutics, often determined by cell-based assays, is one of the most important critical quality attributes. Potency must be monitored throughout the entire drug development cycle as it measures drug activity and provides a direct link to clinical efficacy. An ideal potency assay should represent a drug’s mechanism of action (MOA), as well as be specific and sensitive enough to detect changes and degradations of the product. Thus, the adoption of cell-based potency assays is likely to increase over the forecast period.
Label-free cell-based assay technology is opening new doors for drug discovery applications. In recent years, the technology has emerged as an innovative tool in the field of biochemical binding assays and cellular research. Due to the benefits of its non-invasiveness, integrated cellular response and excellent sensitivity in biochemical binding assays and endogenous cellular systems, the technology is gaining popularity.
Cell based assay market is a highly competitive market with several global and local players. Some of the leading players in this market include DiscoverX Corporation (Eurofins DiscoverX); Thermo Fisher Scientific, Inc.; Cell Assay Innovations, Inc.; InSphero AG; QGel SA; Becton, Dickinson and Company; Promega Corp.; BioVision, Inc.; Marin Biologic Laboratories; Molecular Devices, LLC.; Porsolt; CYTOO SA; Pharmaceutical Product Development (PPD); ProQinase GmbH; Charles River Laboratories International, Inc.; BioAgilytix Labs; SGS Group; Perkin Elmer Inc.; General Electric Company; F. Hoffmann-La Roche AG; Merck KGaA.
The major strategies acquired by the leading players are collaborations, M&A, high investment in R&D, new product launches, and geographical expansion. These strategies help the companies to reinforce their existing product portfolio and regional reach. For instance, in February 2020, Eurofins DiscoverX, the products company of Eurofins Discovery announced their partnership with VelaLabs of Vienna, Austria, in which Eurofins DiscoverX is granting the status of Bioassay Certified CRO to VelaLabs as a certified provider of PathHunter assay services. VelaLabs has successfully demonstrated their capability to expeditiously implement client-sponsored GLP validation programs that use the PathHunter platform. PathHunter bioassays are being adopted by top global pharma and biotech companies as mechanism of action (MOA)-reflective functional assays for potency lot release studies. The simplicity of the platform, coupled with a broad menu, makes it attractive to the clients to drive their drug molecules for filings by using the assays.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
13 April 2022
Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.